AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACRUX LTD

0.015

-0.001-6.25%

Volume:20.06K

Turnover:301.00

Market Cap:6.16M

PE:-0.89

High:0.015

Open:0.015

Low:0.015

Close:0.016

52wk High:0.032

52wk Low:0.012

Shares:410.61M

Float Shares:300.39M

Volume Ratio:0.33

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.017

EPS(LYR):-0.017

ROE:-276.58%

ROA:-69.27%

PB:6.02

PE(LYR):-0.89

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.85%

Capital Flow

Inflow:

Outflow:

News

ACRES Commercial Realty to Issue $879.5 Million in Debt Notes

MT Newswires Live

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

TÜV Rheinland Reinforces Global Contamination Control with Clean Room Validation Services

Acrux Ltd-Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACR.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACR.AU\",,,,,undefined,":{"symbol":"ACR.AU","market":"AU","secType":"STK","nameCN":"ACRUX LTD","latestPrice":0.015,"timestamp":1770354720000,"preClose":0.016,"halted":0,"volume":20059,"delay":0,"changeRate":-0.06250000000000006,"nameEN":"ACRUX LTD","floatShares":300389644,"shares":410608528,"eps":-0.016899,"marketStatus":"Market Closed","change":-0.001,"latestTime":"02-06 16:12:00 AEDT","open":0.015,"high":0.015,"low":0.015,"amount":301,"amplitude":0,"askPrice":0.016,"askSize":389000,"bidPrice":0.015,"bidSize":2333462,"shortable":3,"etf":0,"ttmEps":-0.016899,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.016,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":0.33326023173207603,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACR.AU\",,,,,undefined,":{"symbol":"ACR.AU","floatShares":300389644,"roa":"-69.27%","roe":"-276.58%","lyrEps":-0.016881,"volumeRatio":0.33326023173207603,"shares":410608528,"dividePrice":0,"high":0.015,"amplitude":0,"preClose":0.016,"low":0.015,"week52Low":0.012,"pbRate":"6.02","psRate":"5.18","week52High":0.032,"institutionHeld":0,"latestPrice":0.015,"committee":0.714229,"eps":-0.016899,"divideRate":0,"volume":20059,"delay":0,"ttmEps":-0.016899,"open":0.015,"prevYearClose":0.015,"prevWeekClose":0.015,"prevMonthClose":0.015,"prevQuarterClose":0.015,"fiveDayClose":0.015,"twentyDayClose":0.015,"sixtyDayClose":0.016},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-02-23","symbol":"ACR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1708606800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACR.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605987174","title":"ACRES Commercial Realty to Issue $879.5 Million in Debt Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2605987174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605987174?lang=en_us&edition=fundamental","pubTime":"2026-01-21 16:36","pubTimestamp":1768984580,"startTime":"0","endTime":"0","summary":"ACRES Commercial Realty  said Tuesday that it will issue through a subsidiary $879.5 million in non-recourse, floating-rate notes at a weighted-average cost of the one-month term secured overnight financing rate plus 168 basis points.The transaction is expected to close by Feb. 12.The notes are collateralized by around $1 billion of floating-rate first mortgage loans originated by the company and $200 million in cash, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","ACR","ACR.AU","BK7096","BK4110"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU0868494617.USD","ACR","LU1084165304.USD","LU2756315664.SGD","ACR.AU","LU2106854487.HKD","LU2430703095.HKD","BK4581","LU0345770308.USD","LU1974910355.USD","IE00BFXG1179.USD","LU0170899867.USD","LU2264538146.SGD","IE00BHPRN162.USD","IE00B3S45H60.SGD","CRS.AU","LU1064131342.USD","LU0820562030.AUD","LU2023250843.SGD","ORR","LU1244550494.USD","BK4534","LU0211328371.USD","LU0106831901.USD","LU0345769631.USD","IND.AU","LU1629891620.HKD","LU0683600562.USD","LU0208291251.USD","IE00BN8TJ469.HKD","CRS","IE00BKVL7J92.USD","LU0943347566.SGD","IND","IE0034235188.USD","LU1670627923.USD","LU0820561818.USD","LU2746668461.USD","ORR.AU","IE0034235295.USD","BK7508","LU0251132253.USD","LU0787776722.HKD","CR","LU2065731478.USD","LU0106261372.USD","LU0006306889.USD","LU0345770993.USD"],"gpt_icon":0},{"id":"2592926282","title":"TÜV Rheinland Reinforces Global Contamination Control with Clean Room Validation Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2592926282","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592926282?lang=en_us&edition=fundamental","pubTime":"2025-12-18 11:30","pubTimestamp":1766028600,"startTime":"0","endTime":"0","summary":"Clean rooms are engineered environments designed to tightly control airborne particles, microbial contamination, temperature, humidity and airflow. Their performance directly influences product safety, research accuracy and regulatory compliance. From vaccine production to semiconductor fabrication, even minor deviations can result in compromised output, financial losses or failed audits.Airflow Visualisation Studies to assess air movement and detect turbulence.Airborne Particle Count Testing for classification and monitoring compliance.HEPA/ULPA Filter Integrity Testing to verify filtration performance.Air Change Rate  and Ventilation Performance evaluations to ensure consistent environmental control.Recovery Time Testing to determine how quickly cleanliness levels are restored.Temperature and Humidity Mapping to confirm environmental stability.Microbial Sampling and Testing for aseptic and high-risk environments.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2845451/Clean_Room__Validation.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2845451/Clean_Room__Validation.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/tuv-rheinland-reinforces-global-contamination-control-with-clean-room-validation-services-302642175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK7096","ACR.AU","BK7508","ACR"],"gpt_icon":0},{"id":"2590544005","title":"Acrux Ltd-Divestment of Prilocaine 2.5% and Lidocaine 2.5%, Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544005?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:26","pubTimestamp":1765492008,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUEZ6NNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","ACR.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ACR.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008451}]}}